nach oben

Journal of Clinical Immunology

Erschienen in:

01.11.2008

T Regulatory Cells in Autoimmune Diabetes: Past Challenges, Future Prospects

verfasst von: Jeffrey A. Bluestone, Qizhi Tang, Caitlin E. Sedwick

Erschienen in: Journal of Clinical Immunology | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Accumulating evidence suggests that defective regulation is an essential underlying cause of autoimmunity. The development of type 1 diabetes in the NOD mouse strain it is a complex process that depends on a fine balance between pathogenic and regulatory pathways.

Discussion

We have utilized a series of transgenic and knockout mice to determine the relative importance of regulatory T cells and negative regulatory receptors on the development and progression of type 1 diabetes.

Conclusion

This review will focus on the origins and function of Treg in peripheral self-tolerance. We will summarize the role of Treg in preventing autoimmune diseases, with a particular focus on Type 1 Diabetes (T1D), and discuss the prospects for Treg-based therapies for autoimmune diseases.

Moudgil KD, Sercarz EE. The self-directed T cell repertoire: its creation and activation. Rev Immunogenet. 2000;2:26–37.PubMed

Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 1980;29:1–13.PubMed

Turley S, Poirot L, Hattori M, et al. Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med. 2003;198:1527–37.PubMedCrossRef

Yu L, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A. 2000;97:1701–706.PubMedCrossRef

Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.PubMed

Asano M, Toda M, Sakaguchi N, et al. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184:387–96.PubMedCrossRef

Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD25 + CD4 + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162:5317–26.PubMed

Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol. 2003;4:330–36.PubMedCrossRef

Godfrey VL, Wilkinson JE, Rinchik EM, et al. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci U S A. 1991;88:5528–32.PubMedCrossRef

10.

Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 2002;39:537–45.PubMedCrossRef

11.

Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.PubMedCrossRef

12.

Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.PubMedCrossRef

13.

Wicker LS, Miller BJ, Mullen Y. Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice. Diabetes. 1986;35:855–60.PubMedCrossRef

14.

Bendelac A, Carnaud C, Boitard C, et al. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4 + and Lyt-2 + T cells. J Exp Med. 1987;166:823–32.PubMedCrossRef

15.

Boitard C, Yasunami R, Dardenne M, et al. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med. 1989;169:1669–80.PubMedCrossRef

16.

Herbelin A, Gombert JM, Lepault F, et al. Mature mainstream TCR alpha beta + CD4 + thymocytes expressing L-selectin mediate “active tolerance” in the nonobese diabetic mouse. J Immunol. 1998;161:2620–28.PubMed

17.

Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25 + immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–40.PubMedCrossRef

18.

Lenschow DJ, Herold KC, Rhee L, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 1996;5:285–93.PubMedCrossRef

19.

Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–58.PubMedCrossRef

20.

Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4 + CD25 + regulatory T cells. J Immunol. 2003;171:3348–52.PubMed

21.

Fontenot JD, Rudensky AY. Molecular aspects of regulatory T cell development. Semin Immunol. 2004;16:73–80.PubMedCrossRef

22.

Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, et al. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes. 2002;51:638–45.PubMedCrossRef

23.

Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007;7:585–98.PubMedCrossRef

24.

Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455–65.PubMedCrossRef

25.

Masteller EL, Warner MR, Tang Q, et al. Expansion of functional endogenous antigen-specific CD4 + CD25 + regulatory T cells from nonobese diabetic mice. J Immunol. 2005;175:3053–59.PubMed

26.

Meagher C. J Immunol In Press: (2008).

27.

Tang Q, Bluestone JA. The FoxP3 + regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:129–34.CrossRef

28.

Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+ CD25-naive T cells to CD4 + CD25 + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198:1875–86.PubMedCrossRef

29.

You S, Leforban B, Garcia C, et al. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A. 2007;104:6335–40.PubMedCrossRef

30.

Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–57.PubMedCrossRef

31.

Hsieh CS, Liang Y, Tyznik AJ, et al. Recognition of the peripheral self by naturally arising CD25 + CD4 + T cell receptors. Immunity. 2004;21:267–77.PubMedCrossRef

32.

Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity. 2008;28:100–11.PubMedCrossRef

33.

Izcue A, Powrie F. Special regulatory T-cell review: regulatory T cells and the intestinal tract—patrolling the frontier. Immunology. 2008;123:6–10.PubMedCrossRef

34.

Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2006;7:83–92.PubMedCrossRef

35.

Cederbom L, Hall H, Ivars F. CD4 + CD25 + regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000;30:1538–43.PubMedCrossRef

36.

Misra N, Bayry J, Lacroix-Desmazes S, et al. Cutting edge: human CD4 + CD25 + T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172:4676–80.PubMed

37.

Herman AE, Freeman GJ, Mathis D, et al. CD4+ CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med. 2004;199:1479–89.PubMedCrossRef

38.

You S, Belghith M, Cobbold S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005;54:1415–22.PubMedCrossRef

39.

Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006;212:217–37.PubMedCrossRef

40.

Earle KE, Tang Q, Zhou X, et al. In vitro expanded human CD4 + CD25 + regulatory T cells suppress effector T cell proliferation. Clin Immunol. 2005;115:3–9.PubMedCrossRef

41.

Kim JM, Rudensky A. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev. 2006;212:86–98.PubMedCrossRef

42.

Hill JA, Feuerer M, Tash K, et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity. 2007;27:786–800.PubMedCrossRef

43.

Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4 + T reg cells. J Exp Med. 2006;203:1701–711.PubMedCrossRef

44.

Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+ CD25+ Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17:2844–53.PubMedCrossRef

45.

Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–98.PubMedCrossRef

46.

Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54:1763–69.PubMedCrossRef

Titel: T Regulatory Cells in Autoimmune Diabetes: Past Challenges, Future Prospects
verfasst von: Jeffrey A. Bluestone
Qizhi Tang
Caitlin E. Sedwick
Publikationsdatum: 01.11.2008
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 6/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9242-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2008

Mast Cells and the Adaptive Immune Response

Limited T-Cell Receptor Diversity Predisposes to Th2 Immunopathology: Involvement of Tregs and Conventional CD4 T Cells

The IL-2/CD25 Pathway Determines Susceptibility to T1D in Humans and NOD Mice

Role of TGF-β in the Induction of Foxp3 Expression and T Regulatory Cell Function

Molecular Mechanisms of Regulatory T Cell Development